This dataset is derived from "A Phase 2, Double-blind, Randomised, Placebo-Controlled Study to Evaluate the Safety and Efficacy of H56:IC31® in Reducing the Rate of TB Disease Recurrence in HIV Negative Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis" (ClinicalTrials.gov number: NCT03512249). The results have been reported in The Lancet Infectious Diseases (https://doi.org/10.1016/S1473-3099(24)00814-4) To request access to the data, please contact Tu Hu at tuhu@ssi.dk.